EUVIMEDEUVIMED entdecken
Fallbericht

Reversal of chronic arterial stenosis with biologic therapy including tocilizumab in Takayasu arteritis

Chisako Kitayama, Tsuyoshi Shirai iD, Tokio Katakura, Yusho Ishii, Hiroko Sato, Hiroshi Fujii

Modern Rheumatology Case Reports · 2026

DOI: 10.1093/mrcr/rxag002 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2026. Verfasst von Chisako Kitayama und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Tohoku University Hospital, Sendai, Japan. Hauptthemen laut MEDLINE: Takayasu Arteritis, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 36 Literaturangaben. Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biologic agents have demonstrated efficacy in the treatment of refractory Takayasu arteritis (TAK). Although vascular stenosis is a common manifestation of the chronic phase of TAK, evidence on the effects of biologic therapy on established vascular lesions remains limited. Here, we report a case series of TAK in which chronic arterial stenosis showed marked improvement following treatment with biologic agents. The first case was a 27-year-old woman with stenosis of the left common carotid artery. Initial treatment with prednisolone (PSL) led to clinical improvement; however, the vascular lesion progressed during tapering, despite the normalisation of inflammatory markers. Reinduction with a methylprednisolone pulse and methotrexate led to slight improvement. Subsequent therapy with tocilizumab, followed by golimumab, resulted in significant and sustained improvement in the stenosis. The second case was a 20-year-old woman with wall thickening of the right brachiocephalic artery. Although PSL and methotrexate were initially administered, the progression of left subclavian artery stenosis was detected on ultrasonography before symptom onset, despite normalised inflammatory markers. The introduction of tocilizumab, with increased PSL, led to a notable improvement in the vascular lesions. These cases and a literature review suggest that biologic agents may reverse vascular remodelling in chronic TAK, even in the absence of systemic inflammatory activity. Comprehensive disease assessment using imaging modalities, alongside serum biomarkers, is essential to guide therapeutic decisions and monitor vascular changes. These findings highlight the importance of imaging-based disease monitoring and raise the potential for targeted treatment strategies aimed at both inflammation control and vascular lesion modification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Takayasu ArteritisAntibodies, Monoclonal, HumanizedHumansFemaleAdultYoung AdultTreatment OutcomeMethotrexate

Stichwörter der Autor:innen

Takayasu arteritisarteryfibrosisgolimumabtocilizumab

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedMethotrexate

Autor:innen und Institutionen

  • Department of Rheumatology, Tohoku University Hospital, Sendai, Japan.

ORCID-Profile: Tsuyoshi Shirai

Förderung

  • JSPS KAKENHI

Zitieren

APA

Kitayama, C., Shirai, T., Katakura, T., Ishii, Y., Sato, H., & Fujii, H. (2026). Reversal of chronic arterial stenosis with biologic therapy including tocilizumab in Takayasu arteritis. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxag002

Vancouver

Kitayama C, Shirai T, Katakura T, Ishii Y, Sato H, Fujii H. Reversal of chronic arterial stenosis with biologic therapy including tocilizumab in Takayasu arteritis. Modern Rheumatology Case Reports. 2026. doi:10.1093/mrcr/rxag002

BibTeX
@article{Kitayama2026,
  author = {Kitayama, Chisako and Shirai, Tsuyoshi and Katakura, Tokio and Ishii, Yusho and Sato, Hiroko and Fujii, Hiroshi},
  title = {Reversal of chronic arterial stenosis with biologic therapy including tocilizumab in Takayasu arteritis},
  journal = {Modern Rheumatology Case Reports},
  year = {2026},
  doi = {10.1093/mrcr/rxag002}
}
Kostenlos starten →